Treatment of only one half of the CD4+ PBMCs with cyclic peptides derived from ICAM-1 (cIBR) or LFA-1 (cLAB.L)
Treatment . | Odds ratio*of MTOC polarization in Gag p19+ PBMCs vs Gag p19- PBMCs . | P† . |
|---|---|---|
| Untreated control | 3.94 | < .001 |
| cIBR | 1.84 | .021 |
| cLAB.L | 1.14 | .41 |
| cIBR + cLAB.L | 1.26 | .39 |
Treatment . | Odds ratio*of MTOC polarization in Gag p19+ PBMCs vs Gag p19- PBMCs . | P† . |
|---|---|---|
| Untreated control | 3.94 | < .001 |
| cIBR | 1.84 | .021 |
| cLAB.L | 1.14 | .41 |
| cIBR + cLAB.L | 1.26 | .39 |
One half of the cells were labeled with CMAC, so that it was possible to distinguish conjugates where only one of the cells was treated with peptide. Three independent experiments were performed with CD4+ PBMCs from 3 different HTLV-1-infected patients with HAM/TSP and high viral load. Where 2 cells formed a conjugate, the orientation of the MTOC was noted, and the odds ratio was calculated for polarization of the MTOC in infected versus uninfected cells.
Summary (weighted mean) odds ratio from the 3 experiments
Significance level of odds ratio